GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults.

Popovic V, Leal A, Micic D, Koppeschaar HP, Torres E, Paramo C, Obradovic S, Dieguez C, Casanueva FF

Lancet (London, England)1 Sept 2000Cited by 114 (Europe PMC)

PMID11030292DOI10.1016/s0140-6736(00)02755-0PepBankPUB-11030292

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

01HumanNot a test of GHRP-6 aloneNon-randomized trialSafety outcome
In 125 adults with pituitary disease and 125 healthy adults, the GHRH plus GHRP‑6 test caused no side effects.
In plain wordsIn adults with pituitary disease and in healthy adults, the combined GHRH and GHRP‑6 test caused no side effects.
Peptide
GHRP-6
Outcome
No significant changeSide effects of the GHRH plus GHRP-6 test
Study
n = 250
Outcome group
Adverse events · Whole body
Source sentences
Summary
GH peaks seen after the GHRH/GHRP-6 test did not result in any side-effects and were not affected by age, sex, amount of adipose tissue, or by the GH assay system used.
2 context sentences(design, population, supporting numbers)
Summary · context
125 adult patients with organic pituitary disease and 125 healthy individuals were studied.
Summary · context
All cases and controls were given GHRH 1 microg per kg bodyweight intravenously plus GHRP-6 1 microg per kg intravenously at 0 min and blood samples were obtained during a subsequent 120 min period.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1103029201
02HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome
The GH peak after the GHRH plus GHRP‑6 test was not affected by age, sex, amount of adipose tissue or the GH assay system.
In plain wordsThe growth hormone peak in the combined GHRH and GHRP‑6 test did not depend on age, sex, body fat or the assay used.
Peptide
GHRP-6
Outcome
No significant changeGH peak after GHRH plus GHRP-6 and clinical factors
Study
n = 250
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
GH peaks seen after the GHRH/GHRP-6 test did not result in any side-effects and were not affected by age, sex, amount of adipose tissue, or by the GH assay system used.
2 context sentences(design, population, supporting numbers)
Summary · context
125 adult patients with organic pituitary disease and 125 healthy individuals were studied.
Summary · context
All cases and controls were given GHRH 1 microg per kg bodyweight intravenously plus GHRP-6 1 microg per kg intravenously at 0 min and blood samples were obtained during a subsequent 120 min period.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1103029202
03HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome
The mean GH peak after the GHRH plus GHRP‑6 test was 59.2 microg/L in healthy controls and 4.1 microg/L in GH-deficient cases.
In plain wordsThe combined GHRH and GHRP‑6 test gave a much lower growth hormone peak in GH-deficient adults than in healthy adults.
Peptide
GHRP-6
Outcome
Not applicableGH peak after GHRH plus GHRP-6, controls versus cases
Study
n = 250
Comparator
Healthy controls
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
GH mean peak
59.2 microg/L
controls
GH mean peak
4.1 microg/L
cases
Source sentences
Summary
The GH mean peak after the GHRH/GHRP-6 test was 59.2 microg/L (SD 2.2) for controls and 4.1 microg/L (0.3) for cases, whereas after ITT the mean peak was 14.3 microg/L (1.7) and 0.5 microg/L (0.06), respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
125 adult patients with organic pituitary disease and 125 healthy individuals were studied.
Summary · context
All cases and controls were given GHRH 1 microg per kg bodyweight intravenously plus GHRP-6 1 microg per kg intravenously at 0 min and blood samples were obtained during a subsequent 120 min period.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1103029203
04HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome
The GHRH plus GHRP‑6 test performed well in receiver-operating characteristic curve analysis.
In plain wordsThe combined GHRH and GHRP‑6 test performed well at telling GH-deficient adults from healthy adults.
Peptide
GHRP-6
Outcome
Not applicableROC curve performance of the GHRH plus GHRP-6 test
Study
n = 250
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
The GHRH/GHRP-6 test performed well under the ROC curve analysis.
2 context sentences(design, population, supporting numbers)
Summary · context
125 adult patients with organic pituitary disease and 125 healthy individuals were studied.
Summary · context
All cases and controls were given GHRH 1 microg per kg bodyweight intravenously plus GHRP-6 1 microg per kg intravenously at 0 min and blood samples were obtained during a subsequent 120 min period.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1103029205
05HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome
An evoked GH concentration of at least 15.0 microg/L accurately distinguished healthy from GH-deficient adults after GHRH plus GHRP‑6.
In plain wordsA growth hormone peak of at least 15.0 microg/L in the combined GHRH and GHRP‑6 test separated healthy from GH-deficient adults.
Peptide
GHRP-6
Outcome
Not applicableDiagnostic GH cut-off for the GHRH plus GHRP-6 test
Study
n = 250
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
GH cut-off
≥ 15 microg/L
GHRH/GHRP-6 test
Source sentences
Summary
An evoked GH concentration of > or = 15.0 microg/L accurately distinguishes between healthy and GH-deficient adults.
2 context sentences(design, population, supporting numbers)
Summary · context
125 adult patients with organic pituitary disease and 125 healthy individuals were studied.
Summary · context
All cases and controls were given GHRH 1 microg per kg bodyweight intravenously plus GHRP-6 1 microg per kg intravenously at 0 min and blood samples were obtained during a subsequent 120 min period.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1103029206
06HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome
In adults with pituitary disease and healthy adults, the authors proposed GH values of 20.00 microg/L or more as normal and 10.00 microg/L or less as GH deficient after the GHRH plus GHRP‑6 test.
In plain wordsThe authors proposed growth hormone cut-off values for normal and deficient results in the combined GHRH and GHRP‑6 test in adults.
Peptide
GHRP-6
Outcome
Not applicableProposed clinical GH cut-offs for the GHRH plus GHRP-6 test
Study
n = 250
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
For clinical utility, it is then proposed that values > or = 20.00 microg/L be considered normal and < or = 10.00 microg/L as GH deficient.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1103029207
07HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome
The difference in peak GH between controls and cases was greater (p<0.001) for the GHRH plus GHRP‑6 test than for the insulin tolerance test.
In plain wordsThe combined GHRH and GHRP‑6 test separated healthy and GH-deficient adults more clearly than the insulin tolerance test did.
Peptide
GHRP-6
Outcome
Not applicableDifference between controls and cases, GHRH plus GHRP-6 test versus ITT
Study
n: not reported in source
Comparator
Insulin tolerance test
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
The differential peak responses of controls and cases was greater (p<0.001), for GHRH/GHRP-6 test than for ITT.
2 context sentences(design, population, supporting numbers)
Summary · context
125 adult patients with organic pituitary disease and 125 healthy individuals were studied.
Summary · context
All cases and controls were given GHRH 1 microg per kg bodyweight intravenously plus GHRP-6 1 microg per kg intravenously at 0 min and blood samples were obtained during a subsequent 120 min period.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1103029204

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.